Prognostic Nutritional Index Predicts Morbidity After Curative Surgery for Colorectal Cancer

ConclusionOur work reports that PNI is an independent predictive factor for the development of postoperative complications following curative surgery for CRC.ResumenIntroducciónEl cáncer colorrectal (CCR) constituye un problema sanitario relevante, asociado a una morbimortalidad significativa. A lo largo de las últimas décadas se ha estudiado en profundidad el vínculo que existe entre el cáncer y el estado nutricional e inflamatorio de los pacientes oncológicos, y se han desarrollado múltiples escalas inmunonutricionales, relacionadas principalmente con el pronóstico oncológico de varios tipos de cáncer.Al generarse una interacción entre el tumor y el huésped, se desencadena una reacción inflamatoria sistémica que conduce a una serie de alteraciones neuroendocrinas. Dicha situación favorece una tendencia hacia la anorexia y el catabolismo. Nuestra hipótesis es que el estado nutricional e inflamatorio de los pacientes oncológicos se correlaciona con la morbilidad postoperatoria.MétodosEste es un estudio observacional y prospectivo de cohortes, con pacientes tratados mediante la cirugía curativa para el CCR en nuestro centro, entre septiembre del 2015 y marzo del 2017. El estado nutricional e inflamatorio de los pacientes fue establecido mediante el uso del Prognostic Nutritional Index (PNI). Las complicaciones (globales, graves, infecciosa...
Source: Cirugia Espanola - Category: Surgery Source Type: research

Related Links:

ConclusionsIn this Phase 2 KSCC 1602 trial of bevacizumab plus FTD/TPI, the primary endpoint of PFS was achieved. This combination therapy showed favorable survival outcomes with an acceptable safety profile for elderly patients with previously untreated metastatic colorectal cancer.Clinical trial identificationUMIN000025241.Legal entity responsible for the studyKyushu Study group of Clinical Cancer.FundingTaho Pharmaceutical.DisclosureA. Makiyama: Advisory / Consultancy, Speaker Bureau / Expert testimony: Eli Lily Pharmaceutical; Speaker Bureau / Expert testimony: Chugai Pharmaceutical; Speaker Bureau / Expert testimony: ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundFruquintinib is a potent, highly selective, novel vascular endothelial growth factor receptor (VEGFR) -1, -2, and -3 tyrosine kinase inhibitor. In the phase 3 FRESCO trial1 that led to the drug ’s approval in China, fruquintinib improved the median overall survival in patients with metastatic colorectal cancer (mCRC) in a third-line or later setting when compared to placebo (9.3 vs 6.6 months); hazard ratio was 0.65 (95% CI, 0.51-0.83; P 
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThe RP2D of rSIFN-co was 30ug (1.6  × 107IU) 3x/week for 21days followed by 7 days ’ rest. Anti-tumour activity seen in heavily pre-treated advanced solid tumor patients. especially in HCC. Future plans involve combinations with other immunotherapies.Clinical trial identificationNCT02387307.Legal entity responsible for the studySichuan Huiyang Life Science and Technology Corporation.FundingSichuan Huiyang Life Science and Technology Corporation.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsBiweekly administration of TAS-102 and BV prevents neutropenia and could be one of the treatment options for 3rd line chemotherapy for mCRC.Clinical trial identificationUMIN000030030. 2018/March/01.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThe regimen of regorafenib and PF-03446962 was associated with unacceptable toxicity and did not demonstrate notable clinical activity in patients with refractory metastatic colorectal cancer.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
AbstractArchaea, which form one of four domains of life alongside Eukarya, Bacteria, and giant viruses, have long been neglected as components of the human microbiota and potential opportunistic infectious pathogens. In this review, we focus on methanogenic Archaea, which rely on hydrogen for their metabolism and growth. On one hand, methanogenic Archaea in the gut are functional associates of the fermentative digestion of dietary fibers, favoring the production of beneficial short-chain fatty acids and likely contributing to the weaning reaction during the neonatal window of opportunity. On the other hand, methanogenic Ar...
Source: Clinical Reviews in Allergy and Immunology - Category: Allergy & Immunology Source Type: research
In conclusion, this study failed to prove the safety and efficacy of irinotecan and panitumumab treatment due to insufficient patient accrual. Although LDH and its isozymes changed after initiation of treatment, their ability to predict the tumor response may not surpass that of carcinoembryonic antigen levels.The University Hospital Medical Information Network Clinical Trial Registry: UMIN000007658.
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research
Conclusions World population is aging and the increase in life expectancy is often unhealthy. In particular, musculoskeletal aging, which leads to sarcopenia and osteoporosis, has several causes such as changes in body composition, inflammation, and hormonal imbalance. Sarcopenia, osteoporosis, and more frequently, sarcopenic obesity are commonly associated with aging and frequently closely linked each other, often leading to the development of a frailty syndrome. Frailty syndrome favors an increased risk of loss function in daily activities, for cardiovascular diseases, cancers, falls, and mortality. As the number of eld...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
In this study, the gut microbiota of 30 LC patients and 30 healthy controls were examined via next-generation sequencing of 16S rRNA and analyzed for diversity and biomarkers. We found that there was no decrease in significant microbial diversity (alpha diversity) in LC patients compared to controls (P observed = 0.1422), while the composition (beta diversity) differed significantly between patients and controls (phylum [stress = 0.153], class [stress = 0.16], order [stress = 0.146], family [stress = 0.153]). Controls had a higher abundance of the bacterial phylum Actinobacteria and genus Bifidobacterium, while patients wi...
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
Conclusions A combination of FTD/TPI 35  mg/m2 bid on days 1 –5 and 15–19 and oxaliplatin 85 mg/m2 on days 1 and 15 every 4  weeks could be a suitable regimen for the recommended dose of FTD/TPI plus oxaliplatin in patients with refractory mCRC.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Anorexia | Brain | Cancer | Cancer & Oncology | Colorectal Cancer | Eating Disorders & Weight Management | Neurology | Neurosurgery | Nutrition | Study | Surgery